Baird Medical Secures Indonesian Regulatory Approval for Microwave Ablation Technology

Rhea-AI Summary

Baird Medical Investment Holdings (NASDAQ: BDMD) has secured regulatory approval from the Indonesian Ministry of Health for its microwave ablation (MWA) technology. The approval covers two key products: the Great Wall Microwave Therapeutic Instrument and the Great Wall Disposable Microwave Ablation Needle.

The company's MWA technology is a minimally invasive procedure that uses targeted microwave energy to destroy abnormal tissue while minimizing impact on surrounding areas. This technology is particularly effective in treating thyroid nodules and tumors, offering benefits such as enhanced precision and faster recovery times.

Following this regulatory milestone, Baird Medical plans to expand its distribution network and collaborate with medical institutions across Indonesia, advancing its global strategic expansion in emerging markets.

Positive

• Secured regulatory approval in Indonesia, opening a new market for MWA products
• Expansion into emerging markets strengthens global presence
• Approval covers multiple products, enabling broader market penetration

Negative

• None.

NEW YORK, March 10, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a forward-thinking medical device company specializing in AI-powered surgical robotics and next-generation surgical instruments, and a global leader in microwave ablation (MWA) technology, has received regulatory approval from the Indonesian Ministry of Health (Kementerian Kesehatan Republik Indonesia). This approval includes the Great Wall Microwave Therapeutic Instrument and the Great Wall Disposable Microwave Ablation Needle, laying the foundation for Baird Medical to introduce its advanced minimally invasive treatment solutions across Indonesia.

"This regulatory approval marks a significant step in our global strategic expansion and underscores our commitment to improving patient care with cutting-edge, minimally invasive technologies," said Haimei Wu, Chairwoman of Baird Medical.  "We look forward to collaborating with Indonesian healthcare providers and supporting them with innovative solutions that enhance precision, safety, and patient outcomes.

Microwave ablation is a highly effective, minimally invasive procedure that uses targeted microwave energy to destroy abnormal tissue with minimal impact on surrounding areas. Recognized for its precision and faster recovery times, MWA is widely used for treating conditions such as thyroid nodules and tumors.

With this regulatory milestone, Baird Medical is set to expand its distribution network and collaborate with key medical institutions in Indonesia, reinforcing its commitment to bringing next-generation medical solutions to emerging markets.

About Baird Medical

Baird Medical is a forward-thinking medical device company specializing in minimally invasive diagnostics and treatment. It is dedicated to the research and development of AI-powered surgical robotic systems and innovative minimally invasive surgical instruments. Our mission is to enhance patient outcomes through precision technology and advanced diagnostic solutions. The company's technological roadmap will fully integrate breakthrough innovations from the open-source AI community—leveraging cutting-edge inference models such as Deepseek and Grok3, while fostering strategic collaborations with leading academic institutions. Our vision extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical has deployed its solutions in over 30 prestigious hospitals and clinics across the United States, including Johns Hopkins Hospital, Tulane Medical Center, Weill Cornell Medicine, and Columbia University Medical Center. Baird Medical is also the market leader in China in thyroid microwave ablation devices and consumables. Meanwhile, the company's minimally invasive treatment products are gradually expanding their commercial presence in over 20 countries worldwide.

Forward-Looking Statements

This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as "may", "could", "should", "expect", "intend", "might", "will", "estimate", "anticipate", "believe", "budget", "forecast", "intend", "plan", "potential", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.

Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the United States; (2) changes in general economic conditions; (3) regulatory conditions and developments; (4) changes in applicable laws or regulations; (5) the nature, cost and outcome of pending and future litigation and other legal proceedings instituted against Baird Medical or others; and (5) other risks and uncertainties from time to time described in the Registration Statement relating to the Business Combination and the transition report, including those listed under the sections titled "Risk Factors" therein, and in ExcelFin's other filings with the SEC.

The foregoing list of factors is not exclusive. Additional information concerning certain of these and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

Contact:
Eric Huang, PR Liaison
Baird Medical Investment Holdings Ltd.
Phone: +1 (888) 508-6228
Email: ir@bairdmed.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/baird-medical-secures-indonesian-regulatory-approval-for-microwave-ablation-technology-302396592.html

SOURCE BDMD

FAQ

What products did Baird Medical (BDMD) receive approval for in Indonesia?

Baird Medical received approval for the Great Wall Microwave Therapeutic Instrument and the Great Wall Disposable Microwave Ablation Needle from the Indonesian Ministry of Health.

What medical conditions can Baird Medical's MWA technology treat?

Baird Medical's microwave ablation technology is used for treating thyroid nodules and tumors through minimally invasive procedures.

What are the advantages of Baird Medical's microwave ablation technology?

The technology offers precision targeting of abnormal tissue, minimal impact on surrounding areas, and faster patient recovery times.

How will the Indonesian regulatory approval impact Baird Medical's business expansion?

The approval enables Baird Medical to expand its distribution network and collaborate with medical institutions across Indonesia, strengthening its presence in emerging markets.